Safety of targeting tumor endothelial cell antigens
The mechanisms underlying discrimination between “self” and “non-self”, a central immunological principle, require careful consideration in immune oncology therapeutics where eliciting anti-cancer immunity must be weighed against the risk of autoimmunity due to the self origin of tumors. Whole cell...
Main Authors: | Wagner, Samuel C., Riordan, Neil H., Ichim, Thomas E., Szymanski, Julia, Ma, Hong, Perez, Jesus A., Lopez, Javier, Plata-Munoz, Juan J., Silva, Francisco, Patel, Amit N., Kesari, Santosh |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830034/ |
Similar Items
-
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?
by: Wagner, Samuel C., et al.
Published: (2015) -
Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™
by: Ichim, Thomas E, et al.
Published: (2015) -
Fibroblasts as a practical alternative to mesenchymal stem cells
by: Thomas E. Ichim, et al.
Published: (2018-07-01) -
The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development
by: Ichim, Thomas, et al.
Published: (2011) -
Xenon in the treatment of panic disorder: an open label study
by: Alexander Dobrovolsky, et al.
Published: (2017-06-01)